Release Details

CARLSBAD, Calif., May 29 /PRNewswire-FirstCall/ -- In conjunction with Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) Annual Meeting and Open House, you are invited to listen to Dr. Stanley Crooke's Isis Corporate Update, which will be broadcast live over the Internet on Friday, May 31, at 3:00 pm Pacific Time / 6:00 pm Eastern Time.

    What:      Isis Pharmaceuticals, Inc. Open House Presentation



    When:      Friday, May 31 at 3:00 pm Pacific Time / 6:00 pm Eastern Time



    Where:     http://www.isispharm.com



    How:       Live over the Internet -- Simply log on to the web at the
               address above.



    Contact:   Karen Lundstedt, 760 603 3880

Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs. The Company has commercialized its first product, Vitravene® (fomivirsen), to treat CMV-induced retinitis in AIDS patients. In addition, Isis has 13 antisense products in its development pipeline, with two in late-stage development and six in Phase II human clinical trials. Affinitac™ (LY900003/ISIS 3521), an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung cancer, and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is in Phase III human clinical trials for Crohn's disease. Isis has a broad patent estate, as the owner or exclusive licensee of more than 900 issued patents worldwide. Isis' GeneTrove™ division uses antisense to assist pharmaceutical industry partners in validating and prioritizing potential gene targets through customized services. Ibis Therapeutics™ is a division focused on the discovery of small molecule drugs that bind to RNA. Additional information about Isis is available at www.isispharm.com .

(Minimum Requirements to listen to broadcast: The Windows Media Player software, downloadable free from http://www.microsoft.com/windows/windowsmedia/EN/default.asp , and at least a 28.8Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to isproducers@prnewswire.com.)

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X65044160
SOURCE Isis Pharmaceuticals, Inc.
Web site: http: //www.isispharm.com
CONTACT: Karen Lundstedt of Isis Pharmaceuticals, Inc., +1-760-603-3880
Audio: http: //www.videonewswire.com/event.asp?id=5564